Ipsen presented detailed Phase II LANTIC data at SCALE 2026 showing that corabotase achieved rapid onset, durable clinical benefit, and high patient satisfaction in moderate-to-severe glabellar lines, with sustained effects outperforming Dysport through Week 24 and continued response through Week 36.
Written By: Mahathi Palivela, PharmD
Reviewed By: Pharmacally Editorial Team
Ipsen will present Phase II data from the LANTIC trial evaluating corabotase (IPN10200) for moderate to severe glabellar lines at the SCALE 2026 symposium on May 16, 2026. Recognized as the first molecule in a newly designated therapeutic class, this investigational recombinant neuroinhibitor is under study for three upper facial aesthetic indications: glabellar lines, forehead lines, and lateral canthal lines.
Ipsen reported positive Phase II topline results from LANTIC in September 2025, demonstrating rapid onset and sustained duration of effect in glabellar lines. The study enrolled 727 participants across dose-escalation and dose-finding stages, comparing corabotase to placebo and Dysport. Proof-of-concept data for forehead and lateral canthal lines are expected later in 2026.
Christelle Huguet, PhD, Executive Vice President and Head of Research and Development at Ipsen, stated: “Corabotase was engineered using recombinant protein technology and our proprietary manufacturing capabilities to combine an active catalytic domain with an affinity-enhanced binding domain. Its recognition as a new therapeutic class underscores its scientific differentiation and Ipsen’s neuroscience expertise.”
Designed to enhance receptor affinity, cellular uptake, and resistance to degradation, corabotase aims to prolong neurotransmitter inhibition and reduce muscle activity for extended effects. Step 3 of LANTIC generated proof-of-concept for glabellar lines in 183 patients; ongoing Stages 2 and 3 evaluate all three indications within Ipsen’s broader corabotase program.
Follow-up From SCALE 2026: Phase II LANTIC Data Show Durable Effect With Corabotase
At the SCALE 2026 symposium in Nashville, Ipsen presented detailed Phase II data from Step 3 of the LANTIC trial involving 183 patients with moderate to severe glabellar lines. The study met its primary endpoint, with 66% of patients treated with corabotase 50 ng achieving a statistically significant ≥2-grade composite improvement at Week 4 compared with 0% for placebo (p=0.0001). By comparison, 54.3% of patients treated with Dysport achieved a similar response at Week 4.
Investigators also reported durable efficacy with corabotase. At Week 24, 60.8% of patients receiving corabotase maintained clinically significant improvement, defined as an investigator-assessed severity score of “none” or “mild,” compared with 36.7% for Dysport and 0.2% for placebo. Ipsen additionally noted that corabotase continued to demonstrate greater improvement in line severity versus Dysport through Week 36.
Patient-reported outcomes supported these findings. According to the Subject Level of Satisfaction (SLS) scale, 82.8% of patients treated with corabotase reported being “very satisfied” or “satisfied” with treatment. The investigational recombinant neuroinhibitor also demonstrated a rapid onset of action, with a median onset time of 0.84 days.
Safety findings were consistent across treatment groups, with Ipsen reporting no major safety concerns. The frequency of adverse events was comparable between corabotase, Dysport, and placebo arms. Based on the overall efficacy and durability profile, Ipsen selected the 50 ng dose for further development in the Phase III LAURITE program.
Corabotase is being developed as Ipsen’s first recombinant neuroinhibitor (RNI), a newly designated therapeutic class engineered using recombinant protein technology rather than naturally occurring botulinum toxins. Ipsen stated that doses expressed in nanograms are not directly comparable to conventional unit-based neurotoxin dosing.
Reference
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
About the Writer
Mahathi Palivela (LinkedIn) is pursuing PharmD and has a strong interest in Clinical Pharmacy and Patient safety. She is passionate about handling and analyzing patient data, and translating clinical insights into clear, meaningful summaries. She aims to apply this interest in Medical Writing and Pharmacovigilance, focusing on improving patient outcomes through careful data interpretation and communication.